Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2020 | Changing treatment landscape of relapsed/refractory myeloma

Joshua Richter • 17 Sep 2020
SOHO 2020
Multiple Myeloma Antibodies Belantamab mafodotin Bortezomib Iberdomide Lenalidomide Pomalidomide
DREAMM-2 DREAMM-6

Joshua Richter, MD, Mount Sinai Medical Center, New York, NY, outlines the changing treatment landscape for patients with relapsed/refractory multiple myeloma including the approval of belantamab mafodotin, a BCMA targeting antibody-drug conjugate, as well as melflufen, evaluated in the HORIZON (NCT02963493) and OCEAN (NCT03151811) trials. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Joshua Richter

1:33
Updates from the LINKER-MM1 study: linvoseltamab in R/R multiple myeloma
Joshua Richter • 27 Sep 2023
1:14
Prevention & monitoring of infections in patients with multiple myeloma treated with immunotherapies
Joshua Richter • 27 Sep 2023
1:44
Matching-adjusted indirect comparison of Isa-Kd versus Dara-Rd in relapsed multiple myeloma
Joshua Richter • 27 Sep 2023
1:45
The value of teclistamab in R/R myeloma & strategies to mitigate toxicities
Joshua Richter • 27 Sep 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals